Table 4.

Associations between clinicopathological factors and overall survival among oxaliplatin-treated gastric cancer patients

Clinicopathological factors	Hazard ratio	95 % confidence interval (CI)	p value
MLH1
MLH1 unmethylation	1.000
MLH1 methylation	2.988	1.064–8.394	0.038*
Gender
Male	1.000
Female	0.553	0.143–2.131	0.389
Age (years)
n < 60	1.000
n ≥ 60	0.398	0.142–1.116	0.080
Tumor histology
Intestinal	1.000
Mixed	1.173	0.704–1.955	0.539
Differentiation
Well and moderately differentiated	1.000
Poorly differentiated	0.653	0.184–2.319	0.510
Tumor size
d < 5	1.000
d ≥ 5	1.999	0.794–5.036	0.142
Tumor invasion
T1–T2	1.000
T3–T4	0.596	0.158–2.242	0.444
Lymph node metastasis
N0–N1	1.000
N2–N3	0.727	0.344–1.535	0.403
Peritoneal or distant metastasis
M0	1.000
M1	0.000	0.000	0.980
Tumor stage
I–II	1.000
III–IV	1.544	0.206–11.592	0.673
Vessel invasion
Negative	1.000
Positive	0.533	0.183–1.556	0.250

The multivariate Cox regression model showed that MLH1 methylation was associated with an increased (198.8 %) risk of shorter overall survival compared to MLH1 (HR 2.988, 95 % CI, 1.064–8.394, p = 0.038; Table 4) in oxaliplatin-treated gastric cancer patients. No significant association between the other clinicopathological factors and overall survival was observed. Statistical analysis was performed by the Cox proportional hazards model

p < 0.05 was considered statistically significant

^*p < 0.05